

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The Phase III ECHELON-1 trial comparing brentuximab vedotin (A) with doxorubicin/vinblastine/dacarbazine (AVD) to bleomycin with AVD (ABVD) for patients with previously untreated Stage III/IV classical Hodgkin lymphoma demonstrated which of the following progression-free survival outcomes at 5 years of follow-up?**
 - No significant improvement with A + AVD compared to ABVD
 - Significant improvement with A + AVD compared to ABVD
- Which of the following drug types best describes the mechanism of action of belantamab mafodotin, which is FDA approved for patients with relapsed/refractory multiple myeloma?**
 - Proteasome inhibitor
 - CAR T-cell therapy
 - Anti-BCMA targeted antibody
- On the basis of results from the Phase II KEYNOTE-057 trial, pembrolizumab is approved for which patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer?**
 - All patients with carcinoma in situ
 - Patients with carcinoma in situ who are ineligible for or refuse cystectomy
- Interim results of the Phase II DESTINY-Lung01 study evaluating the antibody-drug conjugate trastuzumab deruxtecan demonstrated promising clinical activity with a high objective response rate and durable responses among patients with nonsquamous non-small cell lung cancer (NSCLC) with which targetable mutations?**
 - KRAS G12C mutations only
 - EGFR mutations only
 - HER2 mutations only
 - MET exon 14 skipping mutations only
 - Both EGFR and HER2 mutations
- Which of the following drug types best describes the mechanism of action of the recently FDA-approved agent selpercatinib for patients with metastatic NSCLC?**
 - ALK inhibitor
 - EGFR inhibitor
 - HER2 inhibitor
 - MET inhibitor
 - RET inhibitor
 - ROS1 inhibitor
- Which of the following regimens recently received FDA approval for the treatment of metastatic colorectal cancer with a BRAF V600E mutation on the basis of data from the BEACON CRC study?**
 - Dabrafenib/trametinib
 - Vemurafenib/cobimetinib
 - Encorafenib/cetuximab
- In the recent presentation at ESMO 2020 by Kelly and colleagues, which of the following outcomes was reported from the Phase III CheckMate 577 trial of adjuvant nivolumab or placebo for patients with resected Stage II or III esophageal or gastroesophageal cancer who had received neoadjuvant chemoradiation therapy?**
 - A significant improvement in disease-free survival with nivolumab
 - No significant difference in disease-free survival between the study arms
- Which of the following adverse events is associated with trastuzumab deruxtecan?**
 - New secondary cancer
 - Ocular toxicity
 - Interstitial lung disease

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. What did the Phase III HER2CLIMB trial demonstrate regarding the activity of tucatinib versus placebo in combination with trastuzumab/capecitabine in patients with previously treated HER2-positive breast cancer and brain metastases?
- a. Tucatinib is not active in patients with brain metastases
 - b. Tucatinib is significantly active in patients with brain metastases
10. Which of the following drug types best describes the mechanism of action of magrolimab?
- a. Hypomethylating agent
 - b. Bcl-2 inhibitor
 - c. Anti-CD47 monoclonal antibody